MorphoSys Competitors
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside | Analysts | Market Cap |
---|---|---|---|---|---|---|---|---|---|
NOVN | Novartis | Hold |
10
|
CHF93.30 | Buy/Sell | CHF105.00 | 15.35% | 9 | CHF190.37B |
ROG | Roche Holding | Hold |
16
|
CHF227.50 | Buy/Sell | CHF307.83 | 19.78% | 9 | CHF183.65B |
BMY | Bristol-Myers Squibb | Hold |
2
|
$44.55 | Buy/Sell | $58.15 | 21.21% | 10 | $90.31B |
ARGX | argenx | Outperform |
4
|
345.00€ | Buy/Sell | 531.81€ | 26.49% | 10 | 20.49€B |
INCY | Incyte | Outperform |
9
|
$57.05 | Buy/Sell | $77.05 | 37.60% | 8 | $12.01B |
REC | Recordati Industria Chimica e ... | Hold |
18
|
51.80€ | Buy/Sell | 48.61€ | -0.68% | 1 | 10.36€B |
ZEAL | Zealand Pharma A/S | Outperform |
8
|
kr653.50 | Buy/Sell | kr357.00 | 24.71% | 2 | kr40.95B |
HIK | Hikma Pharmaceuticals PLC | Outperform |
18
|
£20.28 | Buy/Sell | £28.11 | 44.03% | 9 | £4.42B |
ORNBV | Orion Oyj | Hold |
14
|
37.62€ | Buy/Sell | 42.52€ | 11.64% | 3 | 5.12€B |
ALK B | ALK-Abelló A/S | Outperform |
13
|
kr155.20 | Buy/Sell | kr109.25 | 6.31% | 3 | kr33.91B |
INDV | Indivior PLC | Buy |
14
|
£13.85 | Buy/Sell | £28.89 | 123.32% | 4 | £1.95B |
ALM | Almirall | Outperform |
16
|
9.38€ | Buy/Sell | 11.39€ | 17.27% | 3 | 1.94€B |
XNCR | Xencor | Outperform |
6
|
$21.29 | Buy/Sell | $37.91 | 62.05% | 4 | $1.32B |
COPN | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF73.60 | Buy/Sell | CHF76.55 | 27.12% | 0 | CHF1.14B |
FAE | Faes Farma | Hold |
18
|
3.65€ | Buy/Sell | 3.90€ | 0.00% | 0 | 1.09€B |
PHM | Pharma Mar | Outperform |
13
|
35.84€ | Buy/Sell | 50.20€ | 33.93% | 1 | 536.95€M |
BSLN | Basilea Pharmaceutica | Outperform |
6
|
CHF43.90 | Buy/Sell | CHF65.63 | 50.34% | 0 | CHF529.94M |
DBV | DBV Technologies | Outperform |
5
|
1.24€ | Buy/Sell | 4.07€ | 222.58% | 1 | 115.65€M |
MOLN | Molecular Partners | Outperform |
4
|
CHF3.38 | Buy/Sell | CHF9.50 | 176.63% | 1 | CHF110.77M |
KPTI | Karyopharm Therapeutics | Outperform |
6
|
$1.13 | Buy/Sell | $6.00 | 342.48% | 1 | $118.80M |